Eitr Biologics, Inc.
Biotechnology company developing next-generation, small-format immunotherapeutics based on single-domain antibody architectures and nanotherapeutic delivery concepts. Focus areas include oncology, antibacterial and antiviral programs designed for improved tissue penetration and rapid preclinical development. Headquartered in Sorrento Valley, San Diego. Seeks external partners and collaborators.
Industries
Nr. of Employees
small (1-50)
Products
Oncology therapeutic program (small single-domain bispecifics)
Development program to create small single-domain bispecific molecules intended to improve penetration into solid tumors and enhance immune-cell engagement with tumor cells.
Antibacterial therapeutic program (gram-negative targets)
Program exploring small-format biologics capable of penetrating gram-negative outer membranes to reach novel bacterial targets.
Antiviral therapeutic program (deep tissue reservoir targeting)
Development of small antibody-based molecules designed to reach and clear viral reservoirs located deep within organs and tissues.
Orthogonal Dual-Interacting Nanotherapeutic (ODIN)
A proprietary single domain antibody-based technology platform designed for the rapid development of highly potent immunotherapeutics.
Oncology therapeutic program (small single-domain bispecifics)
Development program to create small single-domain bispecific molecules intended to improve penetration into solid tumors and enhance immune-cell engagement with tumor cells.
Antibacterial therapeutic program (gram-negative targets)
Program exploring small-format biologics capable of penetrating gram-negative outer membranes to reach novel bacterial targets.
Antiviral therapeutic program (deep tissue reservoir targeting)
Development of small antibody-based molecules designed to reach and clear viral reservoirs located deep within organs and tissues.
Orthogonal Dual-Interacting Nanotherapeutic (ODIN)
A proprietary single domain antibody-based technology platform designed for the rapid development of highly potent immunotherapeutics.
Services
External partnerships and collaborations for joint research, discovery, and development of therapeutics.
Discovery workflows and early development support focused on single-domain antibody formats and small bispecific molecules.
Policies, training, and reporting processes to support Investigator compliance with federal financial conflict of interest regulations and related reporting obligations.
External partnerships and collaborations for joint research, discovery, and development of therapeutics.
Discovery workflows and early development support focused on single-domain antibody formats and small bispecific molecules.
Policies, training, and reporting processes to support Investigator compliance with federal financial conflict of interest regulations and related reporting obligations.
Expertise Areas
- Antibody engineering (single-domain formats)
- Nanotherapeutic delivery for enhanced tissue penetration
- Oncology therapeutics (solid tumor penetration)
- Antibacterial therapeutics targeting gram-negative bacteria
Key Technologies
- Single-domain antibodies (sdAb)
- Small-format bispecific antibody design
- Nanotherapeutic delivery systems
- Strategies for LPS/outer-membrane penetration